Fundraising Fox
Abarceo Pharma
Malmö, SE · Founded 2017 · 10 employees on LinkedIn · 2 known investors
Find your way into Abarceo Pharma
Sign up to find every way you can get introduced to Abarceo Pharma
- Your email: who you already know at Abarceo Pharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Abarceo Pharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.
Founders & leadership
Abarceo Pharma was founded in 2017 by Claes Wollheim and Albert Salehi.
Investors · 2
How we know: LU Innovation's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Frequently asked questions
- What does Abarceo Pharma do?
- Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.
- Who founded Abarceo Pharma?
- Abarceo Pharma was founded by Claes Wollheim, Albert Salehi in 2017.
- Who are Abarceo Pharma's investors?
- Abarceo Pharma's investors include LU Innovation, Almi Invest.
- Where is Abarceo Pharma headquartered?
- Abarceo Pharma is headquartered in Malmö, SE.